These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 34397109)

  • 21. Eculizumab salvage therapy for delayed hemolysis transfusion reaction in sickle cell disease patients.
    Dumas G; Habibi A; Onimus T; Merle JC; Razazi K; Mekontso Dessap A; Galactéros F; Michel M; Frémeaux Bacchi V; Noizat Pirenne F; Bartolucci P
    Blood; 2016 Feb; 127(8):1062-4. PubMed ID: 26758914
    [No Abstract]   [Full Text] [Related]  

  • 22. Successful use of eculizumab for treatment of an acute hemolytic reaction after ABO-incompatible red blood cell transfusion.
    Weinstock C; Möhle R; Dorn C; Weisel K; Höchsmann B; Schrezenmeier H; Kanz L
    Transfusion; 2015 Mar; 55(3):605-10. PubMed ID: 25251967
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
    Fisher SA; Brunskill SJ; Doree C; Gooding S; Chowdhury O; Roberts DJ
    Cochrane Database Syst Rev; 2013 Aug; (8):CD004450. PubMed ID: 23963793
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histopathological evidence for macrophage activation driving post-transfusion hyperhaemolysis syndrome.
    Win N; Lucas S; Hebballi S; McKernan A; Hamilton R; Robinson I; Chen F
    Br J Haematol; 2019 Aug; 186(3):499-502. PubMed ID: 31020643
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria.
    Hill A; Rother RP; Wang X; Morris SM; Quinn-Senger K; Kelly R; Richards SJ; Bessler M; Bell L; Hillmen P; Gladwin MT
    Br J Haematol; 2010 May; 149(3):414-25. PubMed ID: 20230403
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Life-threatening delayed hyperhemolytic transfusion reaction in a patient with sickle cell disease: effective treatment with eculizumab followed by rituximab.
    Boonyasampant M; Weitz IC; Kay B; Boonchalermvichian C; Liebman HA; Shulman IA
    Transfusion; 2015 Oct; 55(10):2398-403. PubMed ID: 25989361
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Post-transfusion purpura associated with anti-Baka and anti-PIA2 platelet antibodies and delayed haemolytic transfusion reaction.
    Chapman JF; Murphy MF; Berney SI; Ord J; Metcalfe P; Amess JA; Waters AH
    Vox Sang; 1987; 52(4):313-7. PubMed ID: 3630057
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan.
    Ninomiya H; Obara N; Chiba S; Usuki K; Nishiwaki K; Matsumura I; Shichishima T; Okamoto S; Nishimura JI; Ohyashiki K; Nakao S; Ando K; Kanda Y; Kawaguchi T; Nakakuma H; Harada D; Akiyama H; Kinoshita T; Ozawa K; Omine M; Kanakura Y
    Int J Hematol; 2016 Nov; 104(5):548-558. PubMed ID: 27464489
    [TBL] [Abstract][Full Text] [Related]  

  • 29. C3-mediated extravascular hemolysis in PNH on eculizumab: Mechanism and clinical implications.
    Notaro R; Sica M
    Semin Hematol; 2018 Jul; 55(3):130-135. PubMed ID: 30032749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prophylactic use of eculizumab during surgery in chronic cold agglutinin disease.
    Tjønnfjord E; Vengen ØA; Berentsen S; Tjønnfjord GE
    BMJ Case Rep; 2017 May; 2017():. PubMed ID: 28487302
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Severe refractory idiopathic warm autoimmune haemolytic anaemia responsive to complement inhibition with eculizumab.
    Neave L; Wilson AJ; Lissack M; Scully M
    BMJ Case Rep; 2018 Dec; 11(1):. PubMed ID: 30567234
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical benefit of eculizumab in patients with no transfusion history in the International Paroxysmal Nocturnal Haemoglobinuria Registry.
    Almeida AM; Bedrosian C; Cole A; Muus P; Schrezenmeier H; Szer J; Rosse WF
    Intern Med J; 2017 Sep; 47(9):1026-1034. PubMed ID: 28608499
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Eculizumab as a Treatment for Hyper-Haemolytic and Aplastic Crisis in Sickle Cell Disease.
    Patel I; Odak M; Douedi S; Alshami A; Upadhyaya VD; Hossain M; Anne M; Patel SV
    Eur J Case Rep Intern Med; 2021; 8(10):002824. PubMed ID: 34790624
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complement activation during intravascular hemolysis: Implication for sickle cell disease and hemolytic transfusion reactions.
    Merle NS; Boudhabhay I; Leon J; Fremeaux-Bacchi V; Roumenina LT
    Transfus Clin Biol; 2019 May; 26(2):116-124. PubMed ID: 30879901
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paroxysmal nocturnal haemoglobinuria treatment with eculizumab is associated with a positive direct antiglobulin test.
    Höchsmann B; Leichtle R; von Zabern I; Kaiser S; Flegel WA; Schrezenmeier H
    Vox Sang; 2012 Feb; 102(2):159-66. PubMed ID: 21929681
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hyperhaemolysis syndrome in haemoglobin E / beta thalassaemia responding to cyclophosphamide therapy.
    Senanayake MP; Kuruppu KK; Sumanasena SP; Lamabadusuriya SP
    Ceylon Med J; 2008 Dec; 53(4):134-5. PubMed ID: 19189792
    [No Abstract]   [Full Text] [Related]  

  • 37. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria.
    Brodsky RA; Young NS; Antonioli E; Risitano AM; Schrezenmeier H; Schubert J; Gaya A; Coyle L; de Castro C; Fu CL; Maciejewski JP; Bessler M; Kroon HA; Rother RP; Hillmen P
    Blood; 2008 Feb; 111(4):1840-7. PubMed ID: 18055865
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rare antibody-associated hemolytic transfusion reaction and transfusion-related acute lung injury: a case report.
    Beck TN; Young NG; Erickson ML; Prats I
    BMC Surg; 2017 Apr; 17(1):48. PubMed ID: 28441942
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hyperhaemolysis syndrome responsive to splenectomy in a patient with δβ-thalassaemia: a discussion on underlying mechanisms.
    Vagace JM; Casado MS; Bajo R; Gervasini G
    Blood Transfus; 2014 Jan; 12(1):127-9. PubMed ID: 24333072
    [No Abstract]   [Full Text] [Related]  

  • 40. Delayed haemolytic transfusion reaction and hyperhaemolysis complicating peri-operative blood transfusion in sickle cell disease.
    McGlennan AP; Grundy EM
    Anaesthesia; 2005 Jun; 60(6):609-12. PubMed ID: 15918834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.